

Identification of functionally variant MDR1 alleles among Americans

Clinical Pharmacology and Therapeutics

70, 189-199

DOI: [10.1067/mcp.2001.117412](https://doi.org/10.1067/mcp.2001.117412)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacogenetics of Warfarin Elimination and its Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2001, 40, 587-603.	1.6	278
2	Polymorphisms in OATP-C. <i>Journal of Biological Chemistry</i> , 2001, 276, 35669-35675.	1.6	558
3	Candidate gene approach for pharmacogenetic studies. <i>Pharmacogenomics</i> , 2002, 3, 47-56.	0.6	27
4	In vitro assay-assisted treatment selection for women with breast or ovarian cancer.. <i>Endocrine-Related Cancer</i> , 2002, 9, 171-182.	1.6	44
5	Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. <i>Pharmacogenomics</i> , 2002, 3, 781-790.	0.6	10
6	Pharmacogenetics in diverse ethnic populations – implications for drug discovery and development. <i>Pharmacogenomics</i> , 2002, 3, 493-506.	0.6	13
7	Polymorphism of MDR1 Gene in Healthy Japanese Subjects: A Novel SNP with an Amino Acid Substitution (Glu108Lys). <i>Drug Metabolism and Pharmacokinetics</i> , 2002, 17, 479-481.	1.1	8
8	Drug Transporters: Their Role and Importance in the Selection and Development of New Drugs. <i>Drug Metabolism and Pharmacokinetics</i> , 2002, 17, 93-108.	1.1	65
9	Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional Analysis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 804-813.	1.3	311
10	A Naturally Occurring Mutation in the SLC21A6 Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter. <i>Journal of Biological Chemistry</i> , 2002, 277, 43058-43063.	1.6	127
11	Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 529-534.	5.7	176
12	MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 425-427.	5.7	84
13	Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 437-450.	5.7	266
14	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 451-457.	5.7	186
15	Effects of Polymorphisms of MDR1, MRP1, and MRP2 Genes on Their mRNA Expression Levels in Duodenal Enterocytes of Healthy Japanese Subjects.. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 1356-1359.	0.6	125
16	MDR1 Genotype-Related Pharmacokinetics and Pharmacodynamics.. <i>Biological and Pharmaceutical Bulletin</i> , 2002, 25, 1391-1400.	0.6	167
17	C3435T Mutation in Exon 26 of the Human MDR1 Gene and Cyclosporine Pharmacokinetics in Healthy Subjects. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 400-404.	1.0	84
18	Fexofenadine Transport in Caco-2 Cells: Inhibition with Verapamil and Ritonavir. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1269-1274.	1.0	80

#	ARTICLE	IF	CITATIONS
19	Functional Characterization of Coding Polymorphisms in the HumanMDR1 Gene Using a Vaccinia Virus Expression System. <i>Molecular Pharmacology</i> , 2002, 62, 1-6.	1.0	154
20	Pharmacology of Desloratadine. <i>Clinical Drug Investigation</i> , 2002, 22, 1-11.	1.1	11
21	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , 2002, 359, 30-36.	6.3	635
22	Multidrug resistance and response to antiretroviral treatment. <i>Lancet, The</i> , 2002, 359, 2114.	6.3	3
23	Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. <i>AAPS PharmSci</i> , 2002, 4, 89-94.	1.3	19
24	Understanding neonatal hyperbilirubinaemia in the era of genomics. <i>Seminars in Fetal and Neonatal Medicine</i> , 2002, 7, 143-152.	2.8	57
25	The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. <i>Human Immunology</i> , 2002, 63, 765-770.	1.2	98
26	Evaluating the Potential Impact of Pharmacogenomics on ADRs. <i>Journal of Managed Care Pharmacy</i> , 2002, 8, 285-290.	2.2	2
27	The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1295-1310.	6.6	225
28	Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1311-1331.	6.6	205
29	Pharmacogenomics of organic anion-transporting polypeptides (OATP). <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1343-1352.	6.6	111
30	Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1333-1342.	6.6	54
31	MDR1gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 526-534.	1.1	226
32	MDR1 genotypes do not influence the absorption of a single oral dose of 1â€ƒmg digoxin in healthy white males. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 610-616.	1.1	133
33	The genetic basis of variability in drug responses. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 37-44.	21.5	233
34	Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. <i>Pharmaceutical Research</i> , 2002, 19, 1581-1585.	1.7	107
35	MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. <i>Pharmaceutical Research</i> , 2003, 20, 552-556.	1.7	52
36	Chemotherapy individualization. <i>Investigational New Drugs</i> , 2003, 21, 149-156.	1.2	17

#	ARTICLE	IF	CITATIONS
37	Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. <i>Pharmaceutical Research</i> , 2003, 20, 1163-1169.	1.7	70
38	Population analyses of sustained-release verapamil in patients: Effects of sex, race, and smoking. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 31-40.	2.3	46
39	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 42, 906-925.	2.1	103
40	Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. <i>Pharmaceutical Research</i> , 2003, 20, 38-44.	1.7	38
41	GENETIC POLYMORPHISMS OF THE HUMAN MDR1 DRUG TRANSPORTER. <i>Annual Review of Pharmacology and Toxicology</i> , 2003, 43, 285-307.	4.2	294
42	Implications of pharmacogenetics for individualizing drug treatment and for study design. <i>Journal of Molecular Medicine</i> , 2003, 81, 154-167.	1.7	52
43	Digoxin pharmacokinetics and MDR1 genetic polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 809-812.	0.8	149
44	Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 303-312.	0.8	212
45	Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms. <i>American Journal of Transplantation</i> , 2003, 3, 477-483.	2.6	239
46	Effects of Grapefruit Juice on Intestinal P-glycoprotein: Evaluation Using Digoxin in Humans. <i>Pharmacotherapy</i> , 2003, 23, 979-987.	1.2	55
47	Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. <i>Biochemical Pharmacology</i> , 2003, 65, 1843-1852.	2.0	117
48	Drug transport proteins in the liver. <i>Advanced Drug Delivery Reviews</i> , 2003, 55, 107-124.	6.6	198
49	Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. <i>International Journal of Cancer</i> , 2003, 107, 224-228.	2.3	20
50	Detection of the four sequence variations of MDR1 gene using TaqMan [®] MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. <i>Clinical Biochemistry</i> , 2003, 36, 511-518.	0.8	41
51	MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 195-196.	2.3	19
52	No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 487-498.	2.3	50
53	Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 423-436.	2.3	81
54	The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 182-190.	1.1	70

#	ARTICLE	IF	CITATIONS
55	Importance of P-glycoprotein for drug disposition in humans. <i>European Journal of Clinical Investigation</i> , 2003, 33, 6-9.	1.7	129
56	P-glycoprotein: from genomics to mechanism. <i>Oncogene</i> , 2003, 22, 7468-7485.	2.6	956
57	Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. <i>Pharmacogenomics Journal</i> , 2003, 3, 297-299.	0.9	43
58	Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter Gene ABCB1. <i>New England Journal of Medicine</i> , 2003, 348, 1442-1448.	13.9	690
59	Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. <i>Pharmacogenomics</i> , 2003, 4, 397-410.	0.6	208
60	Pharmacogenomics – Drug Disposition, Drug Targets, and Side Effects. <i>New England Journal of Medicine</i> , 2003, 348, 538-549.	13.9	1,609
61	Role of P-Glycoprotein in Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2003, 42, 59-98.	1.6	757
62	The Influence of Sex on Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2003, 42, 107-121.	1.6	360
63	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, 26-33.	0.6	309
64	MDR1 Ala893 Polymorphism Is Associated with Inflammatory Bowel Disease. <i>American Journal of Human Genetics</i> , 2003, 73, 1282-1292.	2.6	213
65	Simultaneous screening for three mutations in the ABCB1 gene. <i>Genomics</i> , 2003, 82, 503-510.	1.3	19
66	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003, 6, 71-84.	6.5	207
67	Gender differences in pharmacokinetics can be detected but their clinical relevance remains unclear. <i>Drugs and Therapy Perspectives</i> , 2003, 19, 22-26.	0.3	0
68	The Pharmacogenetics of Immunosuppression for Organ Transplantation. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 291-301.	3.3	28
69	Impact of Drug Transporter Studies on Drug Discovery and Development. <i>Pharmacological Reviews</i> , 2003, 55, 425-461.	7.1	475
70	Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 524-530.	1.3	46
71	CYP3A4 and MDR1 Alleles in a Portuguese Population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 1345-50.	1.4	42
72	Pharmacogenomics: marshalling the human genome to individualise drug therapy. <i>Gut</i> , 2003, 52, 10ii-18.	6.1	33

#	ARTICLE	IF	CITATIONS
73	ABC of oral bioavailability: transporters as gatekeepers in the gut. <i>Gut</i> , 2003, 52, 1788-1795.	6.1	263
74	Cytokine Regulation of P-Glycoprotein. <i>Drug Metabolism Reviews</i> , 2003, 35, 19-33.	1.5	51
75	The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 555-564.	1.0	133
76	Simultaneous Genotyping of Seven Single-Nucleotide Polymorphisms in the MDR1 Gene by Single-Tube Multiplex Minisequencing. <i>Clinical Chemistry</i> , 2003, 49, 672-676.	1.5	27
77	Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1889-1896.	3.0	257
78	The Effects of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors on P-Glycoprotein Expression in Peripheral Blood Mononuclear Cells In Vitro. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 551-556.	0.9	89
79	Implications of T-Cell P-Glycoprotein Activity During HIV-1 Infection and Its Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 119-126.	0.9	19
80	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 295-298.	0.9	54
81	Gender, Ethnicity and Genetics in Cardiovascular Disease. <i>Heart Disease (Hagerstown, Md)</i> , 2003, 5, 129-143.	1.3	17
82	Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients ¹ . <i>Transplantation</i> , 2003, 76, 865-868.	0.5	50
83	Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 651-660.	5.7	106
84	Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 741-757.	5.7	141
85	Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 89-95.	5.7	237
86	Pharmacogenetics of hepatocellular transporters. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 189-198.	5.7	41
87	Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 661-674.	5.7	81
88	ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 675-682.	5.7	131
89	Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 595-606.	5.7	238
90	Pharmacogenomics of immunosuppressive drug metabolism. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 607-613.	1.0	25

#	ARTICLE	IF	CITATIONS
91	The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, S51-S60.	1.0	42
92	MDR1 Haplotypes Do Not Affect the Steady-State Pharmacokinetics of Cyclosporine in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1101-1107.	1.0	62
93	Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 66	5.7	361
94	Gender-Specific Implications for Cardiovascular Medication Use in the Elderly. <i>Cardiology in Review</i> , 2003, 11, 275-298.	0.6	30
97	Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. <i>Drug Metabolism and Pharmacokinetics</i> , 2004, 19, 83-95.	1.1	144
98	Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1083-1105.	1.0	193
99	Pharmacogenetics of irinotecan toxicity. <i>Pharmacogenomics</i> , 2004, 5, 835-843.	0.6	71
100	Genetic Polymorphisms in Human Proton-Dependent Dipeptide Transporter PEPT1: Implications for the Functional Role of Pro586. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 437-445.	1.3	61
101	The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date. <i>Clinical Infectious Diseases</i> , 2004, 39, 98-106.	2.9	34
102	<i>MDR1</i> Haplotypes Modify BEN Disease Risk: A Study in Bulgarian Patients with Balkan Endemic Nephropathy Compared to Healthy Controls. <i>Nephron Experimental Nephrology</i> , 2004, 96, e7-e13.	2.4	19
103	The intracellular pharmacology of antiretroviral protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 982-990.	1.3	93
104	Rapid, Long-Range Molecular Haplotyping of Thiopurine S-Methyltransferase (TPMT*) *3A, *3B, and *3C. <i>Clinical Chemistry</i> , 2004, 50, 1528-1534.	1.5	19
105	Pharmacokinetic Interaction between Rifampin and the Combination of Indinavir and Lowâ€Dose Ritonavir in HIVâ€Infected Patients. <i>Clinical Infectious Diseases</i> , 2004, 38, 426-429.	2.9	49
106	Genomic evidence for recent positive selection at the human MDR1 gene locus. <i>Human Molecular Genetics</i> , 2004, 13, 783-797.	1.4	90
107	Pharmacogenomics of MDR1/ABCB1 Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies. <i>Hematology</i> , 2004, 9, 91-105.	0.7	74
108	MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. <i>Journal of Medical Genetics</i> , 2004, 41, e60-e60.	1.5	71
109	Multidrug Resistance Gene G1199A Polymorphism Alters Efflux Transport Activity of P-Glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 1199-1207.	1.3	74
110	Identifying Candidate Causal Variants Responsible for Altered Activity of the ABCB1 Multidrug Resistance Gene. <i>Genome Research</i> , 2004, 14, 1333-1344.	2.4	107

#	ARTICLE	IF	CITATIONS
111	The genetic polymorphism of drug transporters: functional analysis approaches. <i>Pharmacogenomics</i> , 2004, 5, 67-99.	0.6	75
112	Functional Evaluation of ABCB1 (P-Glycoprotein) Polymorphisms: High-Speed Screening and Structure-Activity Relationship Analyses. <i>Drug Metabolism and Pharmacokinetics</i> , 2004, 19, 1-14.	1.1	72
113	Pharmacogenomics of heart failure - focus on drug disposition and action*1. <i>Cardiovascular Research</i> , 2004, 64, 32-39.	1.8	19
114	The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. <i>Pediatric Transplantation</i> , 2004, 8, 551-557.	0.5	38
115	Oral Contraception Does Not Alter Single Dose Saquinavir Pharmacokinetics in Women. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 244-252.	1.1	25
116	MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 548-553.	1.1	72
117	Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. <i>Genes and Immunity</i> , 2004, 5, 530-539.	2.2	168
118	Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. <i>Pharmacogenomics Journal</i> , 2004, 4, 40-48.	0.9	181
119	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. <i>American Journal of Transplantation</i> , 2004, 4, 299-310.	2.6	58
120	Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2004, 72, 314-321.	1.1	172
121	The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 25-51.	1.9	531
122	Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. <i>American Journal of Cardiology</i> , 2004, 93, 1046-1050.	0.7	111
123	Sequence heterogeneity and viral dynamics in cerebrospinal fluid and plasma during antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2004, 10, 33-37.	1.0	2
124	Functional Implications of Genetic Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1). <i>Pharmaceutical Research</i> , 2004, 21, 904-913.	1.7	105
125	Transport Characteristics of Fexofenadine in the Caco-2 Cell Model. <i>Pharmaceutical Research</i> , 2004, 21, 1398-1404.	1.7	116
126	Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. <i>Journal of Human Genetics</i> , 2004, 49, 40-45.	1.1	28
127	Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 69-77.	1.4	45
128	Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. <i>Current Psychiatry Reports</i> , 2004, 6, 364-371.	2.1	54

#	ARTICLE	IF	CITATIONS
129	HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. <i>Prostate</i> , 2004, 61, 248-252.	1.2	13
130	Linkage Disequilibrium and Haplotype Architecture for two ABC Transporter Genes (ABCC1 and ABCG2) in Chinese Population: Implications for Pharmacogenomic Association Studies. <i>Annals of Human Genetics</i> , 2004, 68, 563-573.	0.3	30
131	Pharmacogenomics of antiretroviral therapy. <i>Drug Development Research</i> , 2004, 62, 213-220.	1.4	4
132	Recent advances in pharmacogenetic approaches to anticancer drug development. <i>Drug Development Research</i> , 2004, 62, 233-253.	1.4	42
133	Translating the Genome into individualized therapeutics. <i>Drug Development Research</i> , 2004, 62, 371-382.	1.4	5
134	Determination of fexofenadine in human plasma using 96-well solid phase extraction and HPLC with tandem mass spectrometric detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 35, 837-846.	1.4	37
135	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 13-33.	2.3	781
136	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 422-433.	2.3	171
137	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 38-44.	2.3	222
138	Influence of functional polymorphisms of the gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 220-229.	2.3	77
139	A variant 2677A allele of the gene affects fexofenadine disposition. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 418-427.	2.3	96
140	Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters. <i>Handbook of Analytical Separations</i> , 2004, , 321-353.	0.8	3
141	The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications. <i>Clinical Pharmacokinetics</i> , 2004, 43, 553-576.	1.6	138
142	Genetic Predictors of the Clinical Response to Opioid Analgesics. <i>Clinical Pharmacokinetics</i> , 2004, 43, 983-1013.	1.6	230
143	SEXDIFFERENCES INPHARMACOKINETICS ANDPHARMACODYNAMICS. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 499-523.	4.2	438
144	Linking Pharmacovigilance with Pharmacogenetics. <i>Drug Safety</i> , 2004, 27, 1171-1184.	1.4	19
145	Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. <i>Biochemical and Biophysical Research Communications</i> , 2004, 313, 789-793.	1.0	97
146	Importance of P-glycoprotein at blood-tissue barriers. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 423-429.	4.0	481

#	ARTICLE	IF	CITATIONS
147	Pharmacogenomics in cancer therapy: is host genome variability important?. Trends in Pharmacological Sciences, 2004, 25, 457-464.	4.0	33
148	Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood, 2004, 103, 67-72.	0.6	125
149	Genotype and Allele Frequencies of C3435T Polymorphism of the MDR1 Gene in Various Jewish Populations of Israel. Therapeutic Drug Monitoring, 2004, 26, 679-684.	1.0	18
150	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics and Genomics, 2004, 14, 429-440.	5.7	391
151	Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. Transplantation, 2004, 78, 1182-1187.	0.5	215
152	P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy. Antimicrobial Agents and Chemotherapy, 2004, 48, 1073-1081.	1.4	69
153	Pharmacogenomics of MDR and MRP subfamilies. Personalized Medicine, 2004, 1, 85-104.	0.8	19
154	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation, 2004, 77, 557-561.	0.5	20
155	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2004, 14, 471-478.	5.7	182
156	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics and Genomics, 2004, 14, 147-154.	5.7	409
157	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics and Genomics, 2004, 14, 255-260.	5.7	30
158	Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 1034-1040.	0.9	91
159	Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism. Therapeutic Drug Monitoring, 2004, 26, 180-185.	1.0	170
160	Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics and Genomics, 2004, 14, 381-385.	5.7	75
161	Ritonavir Decreases the Nonrenal Clearance of Digoxin in Healthy Volunteers with Known MDR1 Genotypes. Therapeutic Drug Monitoring, 2004, 26, 322-330.	1.0	55
162	Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics and Genomics, 2004, 14, 309-318.	5.7	104
163	Pharmacogenomics of Drug Transporters: A New Approach to Functional Analysis of the Genetic Polymorphisms of ABCB1 (P-Glycoprotein/MDR1). Biological and Pharmaceutical Bulletin, 2004, 27, 939-948.	0.6	47
164	Simultaneous Determination of Single Nucleotide Polymorphisms of MDR1 Genes by Electrochemical DNA Chip. Drug Metabolism and Pharmacokinetics, 2005, 20, 219-225.	1.1	8

#	ARTICLE	IF	CITATIONS
165	Mechanisms of Drug Interactions II. , 2005, , 41-82.		9
166	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenetics and Genomics, 2005, 15, 693-704.	0.7	419
167	MDR1 Genetic Polymorphisms and Comparison of MDR1 Haplotype Profiles in Korean and Vietnamese Populations. Therapeutic Drug Monitoring, 2005, 27, 531-535.	1.0	36
168	CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenetics and Genomics, 2005, 15, 779-786.	0.7	87
169	Sequential Analysis of Tacrolimus Dosing in Adult Lung Transplant Patients With ABCB1 Haplotypes. Journal of Clinical Pharmacology, 2005, 45, 404-410.	1.0	13
170	Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. Aids, 2005, 19, 2127-2131.	1.0	37
171	Pharmacogenomics of Cholestatic Liver Disease. , 2005, , 407-416.		0
173	Hepatic technetium Tc 99m-labeled sestamibi elimination rate and () genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology and Therapeutics, 2005, 77, 33-42.	2.3	52
174	Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics, 2005, 77, 291-301.	2.3	138
175	Influence of functional haplotypes in the drug transporter gene on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 182-190.	2.3	64
176	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the genetic polymorphism. Clinical Pharmacology and Therapeutics, 2005, 78, 191-201.	2.3	68
177	Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics, 2005, 78, 260-277.	2.3	425
178	Primary prevention with over-the-counter statins: A cautionary tale. Clinical Pharmacology and Therapeutics, 2005, 78, 218-220.	2.3	3
179	Pharmacogenomics and Systems Biology of Membrane Transporters. Molecular Biotechnology, 2005, 29, 75-88.	1.3	11
180	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics, 2005, 6, 115-138.	0.6	114
181	The implications of P-glycoprotein in HIV: friend or foe?. Fundamental and Clinical Pharmacology, 2005, 19, 283-296.	1.0	41
182	Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment. Epilepsia, 2005, 46, 643-647.	2.6	195
183	Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. British Journal of Clinical Pharmacology, 2005, 59, 365-370.	1.1	69

#	ARTICLE	IF	CITATIONS
184	Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding) Tj ETQq0 0 Q r gBT /Overlock 10 T	1.1	134
185	Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 159-171.	1.1	109
186	Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1129-1138.	1.9	60
187	Multidrug Resistance (MDR1) Gene in Inflammatory Bowel Disease: A Key Player?. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 1013-1019.	0.9	16
188	Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy. <i>Epilepsia</i> , 2005, 46, 224-235.	2.6	269
189	Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. <i>European Journal of Pharmacology</i> , 2005, 528, 27-36.	1.7	49
190	Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy. <i>American Journal of Transplantation</i> , 2005, 5, 595-603.	2.6	129
191	Pharmacogenetics for individualized cancer chemotherapy. , 2005, 107, 155-176.		136
192	Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. <i>Arthritis and Rheumatism</i> , 2005, 52, 1349-1359.	6.7	7
193	Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 97-102.	0.8	51
194	Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 72-78.	1.1	76
195	Predicting drug response and toxicity based on gene polymorphisms. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 171-196.	2.0	96
197	Construction of a Functional Transporter Analysis System Using MDR1 Knockdown Caco-2 Cells. <i>Pharmaceutical Research</i> , 2005, 22, 1287-1293.	1.7	34
198	Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 103-128.	1.0	36
199	The Relationship between<i>MDR1</i>Polymorphisms and the Response to Etoposide/Cisplatin Combination Chemotherapy in Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2005, 58, 135.	0.7	0
200	Interaction of erythromycin and clarithromycin with orange juice. <i>Medical Journal of Indonesia</i> , 2005, 14, 78.	0.2	0
201	Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis. <i>Cardiovascular Research</i> , 2005, 67, 419-425.	1.8	32
202	MDR1 Genotype-related Pharmacokinetics: Fact or Fiction?. <i>Drug Metabolism and Pharmacokinetics</i> , 2005, 20, 391-414.	1.1	123

#	ARTICLE	IF	CITATIONS
203	An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore. <i>Drug Metabolism Reviews</i> , 2005, 37, 327-378.	1.5	104
204	Effect of MDR1 Haplotype on Risk of Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 460.	4.9	66
205	Pharmacogenetics in drug regulation: promise, potential and pitfalls. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1617-1638.	1.8	64
206	Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. <i>Pharmacogenomics</i> , 2005, 6, 411-417.	0.6	107
207	Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development. <i>Oncologist</i> , 2005, 10, 104-111.	1.9	116
208	Molecular diagnosis of ATP-binding cassette transporter-related diseases. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 755-767.	1.5	11
209	Cytochrome P450 3A polymorphisms and immunosuppressive drugs. <i>Pharmacogenomics</i> , 2005, 6, 37-47.	0.6	53
210	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. <i>Pharmacogenomics</i> , 2005, 6, 323-337.	0.6	82
211	ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1501-1511.	3.0	208
212	Increased Dose of Lopinavir/Ritonavir Compensates for Efavirenz-Induced Drug-Drug Interaction in HIV-1-Infected Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 63-68.	0.9	37
213	MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. <i>Aids</i> , 2005, 19, 1617-1625.	1.0	47
214	Sex and Racial Differences in Pharmacological Response: Where Is the Evidence? <i>Pharmacogenetics, Pharmacokinetics, and Pharmacodynamics. Journal of Women's Health</i> , 2005, 14, 19-29.	1.5	250
215	HIV/AIDS: A Minority Health Issue. <i>Medical Clinics of North America</i> , 2005, 89, 895-912.	1.1	110
216	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2593-2605.	0.9	9
217	Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2455-2473.	0.9	30
218	Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 487-503.	1.5	20
219	Pharmacogenetics and Drug Development. <i>Annual Reports in Medicinal Chemistry</i> , 2005, , 417-427.	0.5	1
220	METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?. <i>Drug Metabolism and Disposition</i> , 2005, 33, 603-613.	1.7	91

#	ARTICLE	IF	CITATIONS
221	MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. <i>Clinica Chimica Acta</i> , 2005, 359, 46-52.	0.5	17
222	Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. <i>European Journal of Cancer</i> , 2005, 41, 1811-1818.	1.3	23
223	The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions. <i>Drug Safety</i> , 2005, 28, 789-801.	1.4	71
224	Pharmacokinetics of Paclitaxel in Ovarian Cancer Patients and Genetic Polymorphisms of CYP2C8, CYP3A4, and MDR1. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 674-682.	1.0	62
225	Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. <i>Gastroenterology</i> , 2005, 128, 288-296.	0.6	179
226	Evaluation of First-Pass Cytochrome P4503A (CYP3A) and P-Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 79-88.	1.0	27
227	Effect of theMDR1C3435T Variant and P-Glycoprotein Induction on Dicloxacillin Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 411-421.	1.0	18
228	Taxane pharmacogenetics. <i>Personalized Medicine</i> , 2006, 3, 33-43.	0.8	23
229	Comparison of the Risk of Drowsiness and Sedation between Levocetirizine and Desloratadine. <i>Drug Safety</i> , 2006, 29, 897-909.	1.4	37
230	Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 175-185.	1.6	27
231	The ability to predict drug interactions mediated by active drug transport systems can help optimise pharmacotherapy. <i>Drugs and Therapy Perspectives</i> , 2006, 22, 22-26.	0.3	0
232	Genetic Predisposition and Renal Allograft Failure. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 205-219.	1.6	6
233	Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 371-374.	1.5	9
234	CYP3A4 and MDR Mediated Interactions in Drug Therapy. <i>Clinical Research and Regulatory Affairs</i> , 2006, 23, 125-163.	2.1	7
235	Structure, Function, Expression, Genomic Organization, and Single Nucleotide Polymorphisms of Human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) Efflux Transporters. <i>International Journal of Toxicology</i> , 2006, 25, 231-259.	0.6	353
236	Pharmacogenomics in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 21-28.	2.4	30
237	Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer. <i>Clinical Pharmacokinetics</i> , 2006, 45, 253-285.	1.6	139
238	Scientific Perspectives on Drug Transporters and Their Role in Drug Interactions. <i>Molecular Pharmaceutics</i> , 2006, 3, 62-69.	2.3	134

#	ARTICLE	IF	CITATIONS
239	Nutrigenomics and Nutrigenetics. , 2006, , 15-24.		1
240	Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006, 1760, 1866-1873.	1.1	32
241	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. <i>Cancer Letters</i> , 2006, 234, 4-33.	3.2	214
242	MDR1 C3435T Polymorphisms Correlate With Cyclosporine Levels in De Novo Renal Recipients. <i>Transplantation Proceedings</i> , 2006, 38, 2847-2849.	0.3	29
243	Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 nonexpressors. <i>Transplant Immunology</i> , 2006, 15, 235-240.	0.6	63
244	MDR1 Gene Polymorphism in Japanese Patients with Schizophrenia and Mood Disorders Including Depression. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 2446-2450.	0.6	32
245	OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. <i>Blood</i> , 2006, 108, 697-704.	0.6	413
246	The MDR1/ABCB1 Gene, a High-Impact Risk Factor for Cardiac Transplant Rejection. <i>Transplantation</i> , 2006, 82, 1677-1682.	0.5	24
247	Multidrug Resistance Gene-1 (MDR-1) Haplotypes Have a Minor Influence on Tacrolimus Dose Requirements. <i>Transplantation</i> , 2006, 82, 705-708.	0.5	50
248	G2677T and C3435T Genotype and Haplotype Are Associated With Hepatic ABCB1 (MDR1) Expression. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 373-379.	1.0	49
249	In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 855-861.	0.7	40
250	Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 837-845.	0.7	59
251	Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 439-450.	0.7	62
252	Pharmacokinetics of Amrubicin and Its Active Metabolite Amrubicinol in Lung Cancer Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 76-82.	1.0	25
253	Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 441-449.	0.9	146
254	ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. <i>Molecular Neurodegeneration</i> , 2006, 1, 13.	4.4	12
255	EFFECTS OF GENETIC POLYMORPHISMS OF CYP3A4, CYP3A5 AND MDR1 ON CYCLOSPORINE PHARMACOKINETICS AFTER RENAL TRANSPLANTATION. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2006, 33, 1093-1098.	0.9	84
256	Genetic Variations and Haplotype Structures of the ABCB1 Gene in a Japanese Population: An Expanded Haplotype Block Covering the Distal Promoter Region, and Associated Ethnic Differences. <i>Annals of Human Genetics</i> , 2006, 70, 605-622.	0.3	20

#	ARTICLE	IF	CITATIONS
257	Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 979-985.	1.2	38
258	Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 129-135.	0.6	25
259	Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 379-388.	1.1	3
260	Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 440-450.	1.1	40
261	Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 538-544.	1.1	64
262	Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1403-1412.	1.9	13
263	Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and Inflammatory Bowel Disease and their effects on disease behavior: A case-control and meta-analysis study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 263-271.	0.9	87
264	Recent understanding of IBD pathogenesis: Implications for future therapies. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 1068-1083.	0.9	213
265	MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 62-71.	2.3	30
266	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 90-102.	2.3	50
267	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 186-196.	2.3	87
268	MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 325-338.	2.3	91
269	Environmental and genetic factors associated with morphine response in the postoperative period. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 316-324.	2.3	216
270	ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 427-439.	2.3	43
271	Impact of P-glycoprotein on clopidogrel absorption. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 486-501.	2.3	361
272	Effect of CYP3A53 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 646-656.	2.3	53
273	ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 682-690.	2.3	132
274	Application of Pharmacogenomics in Clinical Pharmacology. <i>Toxicology Mechanisms and Methods</i> , 2006, 16, 89-99.	1.3	44

#	ARTICLE	IF	CITATIONS
275	Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey. <i>Molecular Biology Reports</i> , 2006, 33, 295-300.	1.0	25
276	Prediction of systemic exposure to cyclosporine in Japanese pediatric patients. <i>Journal of Human Genetics</i> , 2006, 51, 969-976.	1.1	9
277	The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 933-937.	0.8	66
278	Analyses of single nucleotide polymorphisms and haplotype linkage of the human ABCB1 (MDR1) gene in Korean. <i>Archives of Pharmacal Research</i> , 2006, 29, 1132-1139.	2.7	8
279	MDR1 Gene Polymorphisms and Clinical Relevance. <i>Journal of Genetics and Genomics</i> , 2006, 33, 93-104.	0.3	44
280	P-glycoprotein in the placenta: Expression, localization, regulation and function. <i>Reproductive Toxicology</i> , 2006, 22, 400-410.	1.3	187
281	Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. <i>Toxicology and Applied Pharmacology</i> , 2006, 211, 1-10.	1.3	78
282	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
283	Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. , 2006, 112, 457-473.		319
284	Increased Expression of MDR1 mRNAs and P-glycoprotein in Placentas from HIV-1 Infected Women. <i>Placenta</i> , 2006, 27, 699-706.	0.7	31
285	Effect of Quercetin on the Plasma and Intracellular Concentrations of Saquinavir in Healthy Adults. <i>Pharmacotherapy</i> , 2006, 26, 1255-1261.	1.2	16
286	Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1366-1377.	6.7	122
287	Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. <i>Cancer</i> , 2006, 107, 2850-2857.	2.0	54
288	Hepatobiliary transporters and drug-induced cholestasis. <i>Hepatology</i> , 2006, 44, 778-787.	3.6	260
289	Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. <i>Liver Transplantation</i> , 2006, 12, 775-780.	1.3	98
290	MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-glycoprotein substrate transport in recombinant LLC-PK1 cells. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2293-2308.	1.6	130
291	A Novel MDR1 G1199T Variant Alters Drug Resistance and Efflux Transport Activity of P-Glycoprotein in Recombinant Hek Cells. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2767-2777.	1.6	39
292	Etiology of Balkan Endemic Nephropathy and Associated Urothelial Cancer. <i>American Journal of Nephrology</i> , 2006, 26, 1-11.	1.4	97

#	ARTICLE	IF	CITATIONS
293	Gender: A Possible Determinant in Dosing of Dermatologic Drugs—an overview. <i>Cutaneous and Ocular Toxicology</i> , 2006, 25, 195-210.	0.5	5
294	MDR1 Haplotype Frequencies in Japanese and Caucasian, and in Japanese Patients with Colorectal Cancer and Esophageal Cancer. <i>Drug Metabolism and Pharmacokinetics</i> , 2006, 21, 126-132.	1.1	81
295	Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2340-2348.	0.5	58
296	MDR1 Polymorphisms Predict the Response to Etoposide+Cisplatin Combination Chemotherapy in Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 137-141.	0.6	60
297	Clinical Pharmacology and Pharmacotherapy of Opioid Switching in Cancer Patients. <i>Oncologist</i> , 2006, 11, 765-773.	1.9	52
298	Proarrhythmia. , 2006, , 73-97.		31
299	Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination. <i>Journal of Clinical Oncology</i> , 2006, 24, 4228-4235.	0.8	31
300	Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. <i>Pharmacogenomics</i> , 2006, 7, 987-993.	0.6	79
301	Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. <i>Blood</i> , 2006, 107, 4871-4879.	0.6	62
302	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. <i>Clinical Microbiology Reviews</i> , 2006, 19, 763-787.	5.7	35
303	Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. <i>Expert Opinion on Drug Delivery</i> , 2006, 3, 23-35.	2.4	23
304	ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. <i>Human Molecular Genetics</i> , 2006, 15, 797-805.	1.4	129
305	Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. <i>Clinical Cancer Research</i> , 2006, 12, 5786-5793.	3.2	115
306	Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 758-767.	1.0	55
307	mdr-1 Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 854-859.	3.2	150
308	MDR1 Gene Variants, Indoor Insecticide Exposure, and the Risk of Childhood Acute Lymphoblastic Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1172-1177.	1.1	65
309	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. <i>Pharmacogenomics</i> , 2007, 8, 29-39.	0.6	91
310	Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. <i>Pharmacogenomics Journal</i> , 2007, 7, 56-65.	0.9	148

#	ARTICLE	IF	CITATIONS
311	Function-Altering SNPs in the Human Multidrug Transporter Gene ABCB1 Identified Using a Saccharomyces-Based Assay. <i>PLoS Genetics</i> , 2007, 3, e39.	1.5	53
312	Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. <i>Pharmacogenomics</i> , 2007, 8, 227-235.	0.6	36
313	Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. <i>Pharmacogenomics</i> , 2007, 8, 803-815.	0.6	38
314	Clinical Pharmacogenetics of the Major Adenosine Triphosphate-Binding Cassette and Solute Carrier Drug Transporters. <i>Journal of Pharmacy Practice</i> , 2007, 20, 219-233.	0.5	2
315	Triallelic Single Nucleotide Polymorphisms and Genotyping Error in Genetic Epidemiology Studies: MDR1 (ABCB1) G2677/T/A as an Example. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1185-1192.	1.1	49
316	Pharmacogenetic Considerations in the Management of HIV Infection. <i>Journal of Pharmacy Practice</i> , 2007, 20, 234-245.	0.5	3
317	Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1197-1210.	0.9	17
318	Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials. <i>Clinical Cancer Research</i> , 2007, 13, 7059-7066.	3.2	40
319	Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 685-689.	1.3	19
320	Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. <i>Pharmacogenomics Journal</i> , 2007, 7, 362-365.	0.9	97
321	A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871. <i>Clinical Cancer Research</i> , 2007, 13, 3302-3311.	3.2	40
322	Association of Cumulative Cyclosporine Dose with Its Irreversible Nephrotoxicity in Japanese Patients with Pediatric-Onset Autoimmune Diseases. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 2371-2375.	0.6	12
323	Polymorphisms of Multidrug Resistance Gene (MDR1) and Cyclosporine Absorption in De Novo Renal Transplant Patients. <i>Transplantation</i> , 2007, 83, 1380-1384.	0.5	25
324	ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 127-136.	0.7	35
325	Comparative and evolutionary pharmacogenetics of ABCB1: complex signatures of positive selection on coding and regulatory regions. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 667-678.	0.7	21
326	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 873-883.	0.7	94
327	Promoter polymorphisms and allelic imbalance in ABCB1 expression. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 951-959.	0.7	23
328	Allelic variants of ABC drug transporter Cdr1p in clinical isolates of <i>Candida albicans</i> . <i>Biochemical and Biophysical Research Communications</i> , 2007, 352, 491-497.	1.0	12

#	ARTICLE	IF	CITATIONS
329	Pharmacogenetics and oncology treatment for breast cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 119-127.	0.9	40
330	Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics, 2007, 8, 1169-1178.	0.6	3
331	Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opinion on Pharmacotherapy, 2007, 8, 1441-1449.	0.9	44
332	The Emerging Importance of Transporter Proteins in the Psychopharmacological Treatment of the Pregnant Patient. Drug Metabolism Reviews, 2007, 39, 723-746.	1.5	27
333	Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy. CNS Drugs, 2007, 21, 143-164.	2.7	40
334	Pharmacogenomics of acute leukemia. Pharmacogenomics, 2007, 8, 817-834.	0.6	24
335	Gender differences in drug responses. Pharmacological Research, 2007, 55, 81-95.	3.1	336
336	Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies. Drug Metabolism Reviews, 2007, 39, 159-234.	1.5	673
337	ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics Journal, 2007, 7, 154-179.	0.9	247
338	Equilibrative and Concentrative Transport Mechanisms. , 2007, , 197-227.		6
339	MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 585-590.	0.9	32
340	Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 516-523.	0.9	38
341	Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 2007, 110, 138-147.	2.0	188
342	Enaminones: Exploring Additional Therapeutic Activities. Journal of Pharmaceutical Sciences, 2007, 96, 2509-2531.	1.6	77
343	Pharmacogenetics of paclitaxel metabolism. Critical Reviews in Oncology/Hematology, 2007, 61, 222-229.	2.0	88
344	ABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise. Clinical Pharmacology and Therapeutics, 2007, 81, 265-269.	2.3	129
345	Pharmacogenetics of Opioids. Clinical Pharmacology and Therapeutics, 2007, 81, 429-444.	2.3	298
346	The Effect of ABCB1 Polymorphism on the Pharmacokinetics of Saquinavir Alone and in Combination with Ritonavir. Clinical Pharmacology and Therapeutics, 2007, 82, 389-395.	2.3	18

#	ARTICLE	IF	CITATIONS
347	Induction of Intestinal P-glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 669-678.	2.3	131
348	CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 711-725.	2.3	192
349	The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 87-96.	2.3	221
350	Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1678-1682.	1.4	22
351	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. <i>Clinical Transplantation</i> , 2007, 21, 252-257.	0.8	31
352	Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 53-58.	1.1	42
353	Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 353-362.	1.1	34
354	Effect of MDR1 C3435T polymorphism on cure rates of <i>Helicobacter pylori</i> infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotypes and 23S rRNA genotypes of <i>H. pylori</i> . <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 693-703.	1.9	40
355	Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 411-418.	1.0	40
356	Chemotherapy-induced resistance by ATP-binding cassette transporter genes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1775, 237-262.	3.3	177
357	Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 917-925.	0.8	35
358	Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 635-642.	1.1	20
359	Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 183-201.	2.7	117
360	Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. <i>International Journal of Clinical Oncology</i> , 2007, 12, 284-290.	1.0	22
361	MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. <i>Pediatric Nephrology</i> , 2007, 22, 44-51.	0.9	47
362	The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. <i>International Journal of Colorectal Disease</i> , 2007, 22, 999-1003.	1.0	46
363	Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards. <i>Molecular Biology Reports</i> , 2008, 35, 473-478.	1.0	16
364	P-glycoprotein polymorphism in hypo- and hyper-thyroidism patients. <i>Molecular Biology Reports</i> , 2008, 35, 693-698.	1.0	6

#	ARTICLE	IF	CITATIONS
365	A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. <i>Investigational New Drugs</i> , 2008, 26, 369-379.	1.2	74
366	Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1069-1084.	0.8	77
367	Functional Polymorphism of the Human Multidrug Resistance Gene (MDR1) and Polydipsiaâ€“Hyponatremia in Schizophrenia. <i>NeuroMolecular Medicine</i> , 2008, 10, 362-367.	1.8	22
368	Effect of race on vincristineâ€™associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. <i>Pediatric Blood and Cancer</i> , 2008, 50, 769-771.	0.8	113
369	Genetic variation and response to morphine in cancer patients. <i>Cancer</i> , 2008, 112, 1390-1403.	2.0	125
370	Quercetin pharmacokinetics in humans. <i>Biopharmaceutics and Drug Disposition</i> , 2008, 29, 205-217.	1.1	207
371	Metaâ€™Analysis of the Effect of MDR1 C3435T Polymorphism on Cyclosporine Pharmacokinetics. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 433-444.	1.2	48
372	Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 559-566.	2.3	303
373	Influence of <i>ABCB1</i> and <i>ABCG2</i> polymorphisms on doxorubicin disposition in Asian breast cancer patients. <i>Cancer Science</i> , 2008, 99, 816-823.	1.7	121
374	Association of genetic polymorphisms in <i>SLCO1B3</i> and <i>ABCC2</i> with docetaxelâ€™induced leukopenia. <i>Cancer Science</i> , 2008, 99, 967-972.	1.7	127
375	ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 240-246.	1.1	21
376	<i>MDR1</i> genotypes do not influence the absorption of a single oral dose of 600â€™mg valacyclovir in healthy Chinese Han ethnic males. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 247-254.	1.1	23
377	Lack of Effect of P-glycoprotein Inhibition on Renal Clearance of Dicloxacillin in Patients with Cystic Fibrosis. <i>Pharmacotherapy</i> , 2008, 28, 883-894.	1.2	21
378	Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2008, 42, 89-97.	1.5	70
379	Genetic polymorphisms and the fate of the transplanted organ. <i>Transplantation Reviews</i> , 2008, 22, 131-140.	1.2	41
380	Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study. <i>Pharmacological Research</i> , 2008, 58, 344-347.	3.1	86
382	Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. <i>Xenobiotica</i> , 2008, 38, 802-832.	0.5	499
383	Role of transport proteins in drug discovery and development: a pharmaceutical perspective. <i>Xenobiotica</i> , 2008, 38, 676-708.	0.5	57

#	ARTICLE	IF	CITATIONS
384	Pharmacogenetics in Breast Cancer Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 8027-8041.	3.2	76
385	No Association Between Single Nucleotide Polymorphisms and the Development of Nephrotoxicity After Orthotopic Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 741-745.	0.3	30
386	Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression. <i>Neuron</i> , 2008, 57, 203-209.	3.8	334
387	The influence of 5-HT _{2C} and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. <i>Psychiatry Research</i> , 2008, 160, 308-315.	1.7	55
388	MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1439-1444.	2.5	62
389	Association of a polymorphism of ABCB1 with obesity in Japanese individuals. <i>Genomics</i> , 2008, 91, 512-516.	1.3	25
390	Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. <i>Steroids</i> , 2008, 73, 1052-1059.	0.8	48
391	ABC multidrug transporters: structure, function and role in chemoresistance. <i>Pharmacogenomics</i> , 2008, 9, 105-127.	0.6	854
392	Pharmacogenomics in Rheumatoid Arthritis. <i>Methods in Molecular Biology</i> , 2008, 448, 413-435.	0.4	13
393	Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. <i>Behavioural Brain Research</i> , 2008, 188, 298-303.	1.2	52
394	An update on methotrexate pharmacogenetics in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2008, 9, 439-451.	0.6	57
395	PXR, CAR and HNF4 β genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics Journal</i> , 2008, 8, 139-146.	0.9	56
396	Pharmacogenomics and HIV pharmacotherapy. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 5-8.	1.3	0
397	Interindividual Variability of Methadone Response. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 109-124.	1.6	126
398	A Novel Human Multidrug Resistance Gene<i>MDR1</i> Variant<i>G571A</i> (G191R) Modulates Cancer Drug Resistance and Efflux Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 474-481.	1.3	30
399	Substrate-Dependent Effects of Human <i>ABCB1</i> Coding Polymorphisms. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 435-442.	1.3	49
400	ABCB1 Allele Polymorphism Is Associated with Virological Efficacy in Na ⁺ -ve HIV-Infected Patients on HAART Containing Nonboosted PIs But Not Boosted PIs. <i>HIV Clinical Trials</i> , 2008, 9, 192-201.	2.0	8
401	The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1655-1665.	0.9	4

#	ARTICLE	IF	CITATIONS
402	ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. <i>Human Molecular Genetics</i> , 2008, 17, 2219-2227.	1.4	150
403	Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. <i>Pharmacogenomics Journal</i> , 2008, 8, 248-255.	0.9	14
404	Dietary salt does not influence the disposition of verapamil enantiomers in relation to efflux transporter ABCB1 genetic polymorphism in healthy Korean subjects. <i>Xenobiotica</i> , 2008, 38, 422-434.	0.5	2
405	Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. <i>Pharmacogenomics</i> , 2008, 9, 1267-1284.	0.6	84
406	Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults. <i>Clinical Cancer Research</i> , 2008, 14, 7102-7109.	3.2	135
407	ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. <i>Pharmacogenomics Journal</i> , 2008, 8, 289-296.	0.9	10
408	Genetic variations and gene expression of transporters in drug disposition and response. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 237-254.	1.5	22
409	Pharmacogenomics of importance for paclitaxel chemotherapy. <i>Pharmacogenomics</i> , 2008, 9, 671-674.	0.6	14
410	Probenecid, but Not Cystic Fibrosis, Alters the Total and Renal Clearance of Fexofenadine. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 957-965.	1.0	25
411	MDR1 diplotypes as prognostic markers in multiple myeloma. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 383-389.	0.7	30
412	Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 223-235.	1.1	139
413	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 77-90.	0.7	71
414	Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 299-305.	0.7	73
415	Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 861-868.	0.7	72
416	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 390-402.	0.7	50
417	Polymorphism of Antimalaria Drug Metabolizing, Nuclear Receptor, and Drug Transport Genes among Malaria Patients in Zanzibar, East Africa. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 10-15.	1.0	30
418	Effects of Cyclosporine A on Single-Dose Pharmacokinetics of Intravenous Itraconazole in Patients With Hematologic Malignancies. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 301-305.	1.0	4
419	Biotransformation Enzymes and Drug Transporters Pharmacogenetics in Relation to Immunosuppressive Drugs: Impact on Pharmacokinetics and Clinical Outcome. <i>Transplantation</i> , 2008, 85, S19-S24.	0.5	36

#	ARTICLE	IF	CITATIONS
420	ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients. Brazilian Journal of Medical and Biological Research, 2008, 41, 769-772.	0.7	22
421		0.1	0
422	Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease. Current Pharmacogenomics and Personalized Medicine, 2009, 7, 1-26.	0.2	18
423	<i>MDR1</i> Single Nucleotide Polymorphism G2677T/A and Haplotype Are Correlated with Response to Docetaxel-Cisplatin Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Respiration, 2009, 78, 49-55.	1.2	52
424	A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Annals of Oncology, 2009, 20, 175-181.	0.6	116
425	Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics Journal, 2009, 9, 194-201.	0.9	11
426	Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma. Clinical Cancer Research, 2009, 15, 1496-1503.	3.2	64
427	Perioperative Genomic Profiles Using Structure-Specific Oligonucleotide Probes. Clinical Medicine and Research, 2009, 7, 69-84.	0.4	6
428	Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. Journal of Antimicrobial Chemotherapy, 2009, 64, 1071-1079.	1.3	46
429	Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men. Clinical Therapeutics, 2009, 31, 999-1006.	1.1	13
430	ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochemical Pharmacology, 2009, 77, 66-75.	2.0	35
431	Characterization of pharmacogenetically relevant <i>CYP2D6</i> and <i>ABCB1</i> gene polymorphisms in a Portuguese population sample. Cell Biochemistry and Function, 2009, 27, 251-255.	1.4	17
432	Associations between ABCB1/MDR1 gene polymorphisms and Crohn's disease: A gene-wide study in a pediatric population. Inflammatory Bowel Diseases, 2009, 15, 900-908.	0.9	23
433	Detection of C1236T, G2677T/A, and C3435T polymorphism of <i>MDR1</i> by amplification refractory mutation system PCR. Journal of Clinical Laboratory Analysis, 2009, 23, 110-116.	0.9	19
434	MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients. Pharmaceutical Research, 2009, 26, 1590-1595.	1.7	18
435	Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and Simulation to Evaluate Fexofenadine as a Probe for Hepatobiliary Transport Function. Pharmaceutical Research, 2009, 26, 1942-1951.	1.7	14
436	Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. European Journal of Clinical Pharmacology, 2009, 65, 239-247.	0.8	32
437	Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. European Journal of Clinical Pharmacology, 2009, 65, 593-600.	0.8	13

#	ARTICLE	IF	CITATIONS
438	Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 413-421.	1.1	53
439	Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 395-401.	1.1	11
440	Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 605-608.	2.3	16
441	Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 130-137.	1.2	111
442	The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the <i>OPRM1</i> and <i>ABCB1</i> genes. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 517-524.	1.0	92
443	A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2009, 1794, 860-871.	1.1	281
444	Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. <i>Schizophrenia Research</i> , 2009, 110, 90-94.	1.1	35
445	Pharmacokinetic Study of the Variability of Indinavir Drug Levels when Boosted with Ritonavir in HIV-Infected Children. <i>Pharmacology</i> , 2009, 83, 59-66.	0.9	18
446	Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. <i>Pharmacological Reports</i> , 2009, 61, 843-850.	1.5	31
447	Gender and interindividual variability in pharmacokinetics. <i>Drug Metabolism Reviews</i> , 2009, 41, 408-421.	1.5	90
448	Treatment of steroid-naive ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1449-1460.	0.9	7
449	Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2009, 80, 325-329.	1.2	25
450	CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1483-1487.	1.0	20
451	Genetic determinants of response to statins. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 977-983.	0.6	17
452	Pharmacokinetics in special populations. <i>Drug Metabolism Reviews</i> , 2009, 41, 422-454.	1.5	20
453	Association of the MDR1 (ABCB1) gene 3435C>T polymorphism with male infertility. <i>Pharmacological Reports</i> , 2009, 61, 690-696.	1.5	19
454	Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 77-85.	0.7	33
457	A Fast SSP-PCR Method for Genotyping the ATP-Binding Cassette Subfamily B Member 1 Gene C3435T and G2677T Polymorphisms in Chinese Transplant Recipients. <i>Tumori</i> , 2009, 95, 338-342.	0.6	2

#	ARTICLE	IF	CITATIONS
458	Pharmacogenetics in Oncology: A Promising Field. <i>Current Pharmaceutical Design</i> , 2010, 16, 155-163.	0.9	17
459	Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review. <i>Current Drug Metabolism</i> , 2010, 11, 115-128.	0.7	113
460	MDR1 3435T and 1236T alleles delay disease progression to pediatric AIDS but have no effect on HIV-1 vertical transmission. <i>Aids</i> , 2010, 24, 833-840.	1.0	7
461	Pharmacogenetics of Drug Transporters. <i>Current Pharmaceutical Design</i> , 2010, 16, 220-230.	0.9	93
462	ATP-Binding Cassette Subfamily B Member 1 Polymorphisms Do Not Determine Cyclosporin Exposure, Acute Rejection or Nephrotoxicity After Heart Transplantation. <i>Transplantation</i> , 2010, 89, 75-82.	0.5	13
464	Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. <i>Blood</i> , 2010, 116, 6144-6145.	0.6	43
466	Role of physiological factors in predicting the risk of oncological diseases on the basis of the polymorphism of the xenobiotic metabolism enzyme system. <i>Human Physiology</i> , 2010, 36, 723-736.	0.1	1
467	Rapid RP-LC Method with Fluorescence Detection for Analysis of Fexofenadine in Human Plasma. <i>Chromatographia</i> , 2010, 71, 1081-1086.	0.7	8
468	Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 251-258.	1.1	83
469	Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 95-105.	1.1	55
470	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 865-870.	0.8	7
471	Pharmacogenetics and forensic toxicology. <i>Forensic Science International</i> , 2010, 203, 53-62.	1.3	56
472	Improving the oral bioavailability of beneficial polyphenols through designed synergies. <i>Genes and Nutrition</i> , 2010, 5, 75-87.	1.2	134
473	Pharmacogenetics of Membrane Transporters: An Update on Current Approaches. <i>Molecular Biotechnology</i> , 2010, 44, 152-167.	1.3	103
474	ABCB1 single nucleotide polymorphisms in the Brazilian population. <i>Molecular Biology Reports</i> , 2010, 37, 111-118.	1.0	14
475	A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. <i>Investigational New Drugs</i> , 2010, 28, 91-97.	1.2	97
476	Emerging New Technologies in Pharamcogenomics: Rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1)., 2010, 126, 69-81.		38
477	Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: A randomized, open-label, parallel-group, single- and multiple-dose study. <i>Clinical Therapeutics</i> , 2010, 32, 206-216.	1.1	18

#	ARTICLE	IF	CITATIONS
478	Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. <i>International Journal of Hygiene and Environmental Health</i> , 2010, 213, 140-145.	2.1	64
479	Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations. <i>Infection, Genetics and Evolution</i> , 2010, 10, 60-67.	1.0	6
480	Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and <i>ABCB1</i> . <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 27-37.	1.1	43
481	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. <i>British Journal of Cancer</i> , 2010, 102, 1003-1009.	2.9	160
482	Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. <i>Acta Pharmacologica Sinica</i> , 2010, 31, 753-758.	2.8	17
483	Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. <i>Annals of the New York Academy of Sciences</i> , 2010, 1187, 184-207.	1.8	83
484	Novel insertion mutation of <i>ABCB1</i> gene in an ivermectin-sensitive Border Collie. <i>Journal of Veterinary Science</i> , 2010, 11, 341.	0.5	9
485	Genetic Factors Influencing Severe Atazanavir-Associated Hyperbilirubinemia in a Population with Low UDP-Glucuronosyltransferase 1A1*28 Allele Frequency. <i>Clinical Infectious Diseases</i> , 2010, 51, 101-106.	2.9	59
486	Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. <i>Pharmacogenomics</i> , 2010, 11, 23-31.	0.6	67
487	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. <i>Pharmacogenomics</i> , 2010, 11, 703-714.	0.6	97
488	Multidrug Resistance 1 (MDR1) Gene Polymorphisms in Childhood Drug-Resistant Epilepsy. <i>Journal of Child Neurology</i> , 2010, 25, 1485-1490.	0.7	27
489	Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation. <i>Pharmacological Reviews</i> , 2010, 62, 1-96.	7.1	679
491	Pharmacogenetic interactions between <i>ABCB1</i> and <i>SLCO1B1</i> tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. <i>Pharmacogenomics</i> , 2010, 11, 1065-1076.	0.6	42
492	Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. <i>Pharmacological Reports</i> , 2010, 62, 1159-1169.	1.5	44
493	Membrane Transporters and Drug Development: Relevance to Pharmacogenomics, Nutrigenomics, Epigenetics, and Systems Biology. <i>Methods in Molecular Biology</i> , 2010, 637, 1-21.	0.4	10
494	Drug transporter pharmacogenetics in nucleoside-based therapies. <i>Pharmacogenomics</i> , 2010, 11, 809-841.	0.6	60
495	Haplotype-Based Analysis of MDR1/ABCB1 Gene Polymorphisms in a Turkish Population. <i>DNA and Cell Biology</i> , 2010, 29, 83-90.	0.9	15
496	Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I. <i>Clinical Pharmacokinetics</i> , 2010, 49, 141-175.	1.6	282

#	ARTICLE	IF	CITATIONS
497	Pharmacogenetic Analysis of Calcineurin Inhibitors in Renal Transplant Patients: Towards Personalized Immunosuppressive Therapy?. Indian Journal of Transplantation, 2010, 4, 5-14.	0.0	0
498	Impact of Nuclear Receptors CAR, PXR, FXR, and VDR, and Their Ligands On Enzymes and Transporters. , 2010, , 75-105.		2
499	Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology, 2010, 59, 474-479.	2.0	41
500	Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience, 2010, 169, 378-387.	1.1	19
501	The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 953-965.	1.5	27
502	Pharmacogenetics of ATP-Binding Cassette Transporters and Clinical Implications. Methods in Molecular Biology, 2010, 596, 95-121.	0.4	54
503	P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 603-619.	1.5	64
504	Clinical significance of ABCB1 genotyping in oncology. Journal of Oncology Pharmacy Practice, 2010, 16, 39-44.	0.5	50
505	<i>ABCB1</i> gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics, 2010, 11, 1715-1723.	0.6	36
506	ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 571-589.	1.5	21
507	Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety. Journal of Clinical Pharmacology, 2010, 50, 659-666.	1.0	80
508	Association between ABCB1 (MDR1) Gene 3435 C>T Polymorphism and Colchicine Unresponsiveness of FMF Patients. Renal Failure, 2011, 33, 899-903.	0.8	26
509	Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-120.	0.9	81
510	Principles of Pharmacology. Pediatric Clinics of North America, 2011, 58, 11-19.	0.9	6
511	Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. Pharmacological Reports, 2011, 63, 815-825.	1.5	20
512	Pharmacogenetics of drug transporters in the enterohepatic circulation. Pharmacogenomics, 2011, 12, 611-631.	0.6	33
514	Immunosuppressants Pharmacogenomics. , 2011, , 249-265.		0
515	Genetic determinants of on-clopidogrel high platelet reactivity. Platelets, 2011, 22, 399-407.	1.1	48

#	ARTICLE	IF	CITATIONS
516	Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. <i>Pharmacological Reports</i> , 2011, 63, 808-814.	1.5	35
517	An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. <i>Pharmacogenomics Journal</i> , 2011, 11, 315-325.	0.9	59
518	Functional analysis of genetic variations in the 5' flanking region of the human MDR1 gene. <i>Molecular Genetics and Metabolism</i> , 2011, 102, 91-98.	0.5	14
519	P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations. <i>Handbook of Experimental Pharmacology</i> , 2011, , 261-283.	0.9	162
520	CYP3A5, ABCB1, and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-Infected Children. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 417-424.	1.0	29
521	ATP-Binding Cassette Efflux Transporters in Human Placenta. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 674-685.	0.9	79
522	Very important pharmacogene summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 152-161.	0.7	366
523	Genetic Variability and Haplotype Profile of MDR1 (ABCB1) in Roma and Hungarian Population Samples with a Review of the Literature. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 206-215.	1.1	33
524	ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells. <i>Respirology</i> , 2011, 16, 1228-1234.	1.3	5
525	Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 614-624.	0.7	43
526	Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. , 2011, 129, 267-289.		52
527	Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 967-988.	1.5	21
528	The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions. , 2011, , 285-313.		2
529	The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment. <i>Pharmacogenomics</i> , 2011, 12, 1465-1483.	0.6	10
530	Influence of MDR1 Polymorphism on H. pylori-Related Chronic Gastritis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 103-108.	1.1	9
531	YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. <i>Investigational New Drugs</i> , 2011, 29, 1337-1346.	1.2	18
532	Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. <i>Molecular Biology Reports</i> , 2011, 38, 2939-2943.	1.0	27
533	Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. <i>Psychopharmacology</i> , 2011, 215, 367-377.	1.5	23

#	ARTICLE	IF	CITATIONS
534	Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 47-54.	0.8	42
535	Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 693-700.	0.8	70
536	A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1131-1137.	0.8	34
537	MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. <i>Medical Oncology</i> , 2011, 28, 1549-1554.	1.2	20
538	Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. <i>Archives of Pharmacal Research</i> , 2011, 34, 1817-1828.	2.7	16
539	Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2308-2317.	0.9	20
540	Evolving Knowledge of Opioid Genetics in Cancer Pain. <i>Clinical Oncology</i> , 2011, 23, 418-428.	0.6	19
541	Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. <i>International Journal of Pharmaceutics</i> , 2011, 415, 15-28.	2.6	147
542	Buspirone, fexofenadine, and omeprazole: Quantification of probe drugs and their metabolites in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 1127-1135.	1.4	8
543	MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3968-3974.	0.4	47
544	Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 9-22.	1.0	14
545	The Impact of Gender on Antidepressants. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 8, 231-249.	0.8	27
546	Impact of ABCB1 Allelic Variants on QTc Interval Prolongation. <i>Clinical Cancer Research</i> , 2011, 17, 937-946.	3.2	19
547	Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism. <i>Oncologist</i> , 2011, 16, 820-834.	1.9	65
548	Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. <i>Pharmacogenomics</i> , 2011, 12, 1525-1533.	0.6	90
549	Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. <i>Xenobiotica</i> , 2012, 42, 1248-1254.	0.5	16
550	Potential of Vincristine Toxicity with Concomitant Fluconazole Prophylaxis in Children with Acute Lymphoblastic Leukemia. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 62-67.	0.3	24
551	Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2). <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 85-105.	1.1	134

#	ARTICLE	IF	CITATIONS
552	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicity in de novo acute myeloid leukemia with normal karyotype. <i>Pharmacogenomics Journal</i> , 2012, 12, 111-118.	0.9	38
554	Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2012, 13, 615-624.	0.6	26
555	Rapid genotyping assays for the 4â€“base pair deletion of canine MDR1/ABCB1 gene and low frequency of the mutant allele in Border Collie dogs. <i>Journal of Veterinary Diagnostic Investigation</i> , 2012, 24, 127-134.	0.5	17
556	Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 122-131.	1.1	80
557	A Case for Pharmacogenomics in Management of Cardiac Arrhythmias. <i>Indian Pacing and Electrophysiology Journal</i> , 2012, 12, 54-64.	0.3	2
560	Mechanisms and Genetics of Drug Transport. , 2012, , 217-237.		0
561	ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. <i>Translational Psychiatry</i> , 2012, 2, e198-e198.	2.4	61
563	Variant genotypes of MDR1 C3435T increase the risk of leukemia: evidence from 10 caseâ€“control studies. <i>Leukemia and Lymphoma</i> , 2012, 53, 1183-1187.	0.6	11
564	Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1551-1560.	1.2	6
565	Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. <i>Pediatric Nephrology</i> , 2012, 27, 1511-1517.	0.9	19
566	Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. <i>Journal of Surgical Research</i> , 2012, 178, 988-995.	0.8	17
567	Pharmacogenomics of Beta-Blockers and Statins: Possible Implications for Perioperative Cardiac Complications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2012, 26, 1101-1114.	0.6	5
568	ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 48, 132-136.	0.6	29
571	Multifactorial Etiology of Gastric Cancer. <i>Methods in Molecular Biology</i> , 2012, 863, 411-435.	0.4	122
572	Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. <i>Journal of the Neurological Sciences</i> , 2012, 315, 72-76.	0.3	18
573	Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China. <i>Acta Pharmacologica Sinica</i> , 2012, 33, 1563-1570.	2.8	14
574	Pharmacogenomics of opioids and perioperative pain management. <i>Pharmacogenomics</i> , 2012, 13, 1719-1740.	0.6	92
575	Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. <i>Rheumatology International</i> , 2012, 32, 3127-3130.	1.5	20

#	ARTICLE	IF	CITATIONS
576	Pharmacogenomic Mechanisms of Drug Toxicity. , 2012, , 285-306.		0
577	Bloodâ€‘brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJMIMI Research, 2012, 2, 57.	1.1	53
578	Genetic variability and haplotype profile of MDR1 in Saudi Arabian males. Molecular Biology Reports, 2012, 39, 10293-10301.	1.0	9
579	Chemotherapy and Mechanisms of Resistance in Breast Cancer. , 2012, , .		0
581	Pharmacogenomics Dictate Pharmacokinetics: Polymorphisms in Drug-Metabolizing Enzymes and Drug-Transporters. , 0, , .		0
582	ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients. Journal of Cancer Research and Clinical Oncology, 2012, 138, 959-969.	1.2	19
583	Genotypic screening of the main opiateâ€‘related polymorphisms in a cohort of 139 sickle cell disease patients. American Journal of Hematology, 2012, 87, 534-536.	2.0	21
584	Unusual high dose of tacrolimus in liver transplant patient, a case report. International Journal of Clinical Pharmacy, 2012, 34, 269-271.	1.0	6
585	Interactions between antidepressants and Pâ€‘glycoprotein at the bloodâ€‘brain barrier: clinical significance of <i>in vitro</i> and <i>in vivo</i> findings. British Journal of Pharmacology, 2012, 165, 289-312.	2.7	171
586	Impact of <i>ABCB1</i> Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 199-204.	1.2	36
587	Cardiovascular pharmacogenetics. , 2012, 133, 280-290.		19
588	MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. BMC Gastroenterology, 2013, 13, 57.	0.8	36
589	Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy. Journal of Pharmaceutical Sciences, 2013, 102, 3189-3195.	1.6	6
590	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. International Journal of Legal Medicine, 2013, 127, 579-586.	1.2	18
591	Update on the Management of Postoperative Nausea and Vomiting. Drugs, 2013, 73, 1525-1547.	4.9	120
592	Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings, 2013, 45, 137-141.	0.3	16
593	Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: Impact on susceptibility and response to steroids. Gene, 2013, 530, 201-207.	1.0	27
594	Influence of ABCB1 genetic variants in breast cancer treatment outcomes. Cancer Epidemiology, 2013, 37, 754-761.	0.8	25

#	ARTICLE	IF	CITATIONS
595	Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children. <i>Gene</i> , 2013, 522, 96-101.	1.0	18
596	Resistance to ondansetron: Role of pharmacogenetics in post-operative nausea and vomiting. <i>Egyptian Journal of Medical Human Genetics</i> , 2013, 14, 331-336.	0.5	8
597	Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 1636-1644.	0.3	34
598	Genotype Variability and Haplotype Frequency of <i>MDR1</i> (<i>ABCB1</i>) Gene Polymorphism in Morocco. <i>DNA and Cell Biology</i> , 2013, 32, 582-588.	0.9	16
599	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. <i>International Journal of Pharmaceutics</i> , 2013, 452, 14-35.	2.6	63
602	<i>MDR1</i> polymorphisms associated with risk and survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1188-1193.	0.6	14
603	Immunobiology of Acute Leukemia. , 2013, , 241-283.		1
605	MDR-1 and GST polymorphisms are involved in myelodysplasia progression. <i>Leukemia Research</i> , 2013, 37, 970-973.	0.4	8
606	Fetal polymorphisms at the <i>ABCB1</i> -transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations. <i>European Journal of Human Genetics</i> , 2013, 21, 1436-1441.	1.4	6
607	Association between the <i>MDR1</i> gene variant C3435T and risk of leukaemia: a meta-analysis. <i>European Journal of Cancer Care</i> , 2013, 22, 617-625.	0.7	8
608	Associations between the functional polymorphisms in the <i>ABCB1</i> transporter gene and colorectal cancer risk: a case-control study in Turkish population. <i>Toxicology Mechanisms and Methods</i> , 2013, 23, 235-239.	1.3	6
609	Meta-Analysis of <i>ABCB1</i> 3435C>T Polymorphism and Colorectal Cancer. <i>Pakistan Journal of Medical Sciences</i> , 2013, 29, 1269-74.	0.3	4
610	Organic anion-transporting polypeptides (OATPs/SLCOs). , 2013, , 353-454.		0
611	Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions. <i>Pharmacogenomics</i> , 2013, 14, 1745-1764.	0.6	17
612	The Vitreous, the Retinal Interface in Ocular Health and Disease. <i>Ophthalmologica</i> , 2013, 230, 165-178.	1.0	71
613	Influence of <i>CYP3A5</i> 6986A>G and <i>ABCB1</i> 3435C>T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 67-78.	0.8	5
614	Functional G1199A <i>ABCB1</i> Polymorphism May Have an Effect on Cyclosporine Blood Concentration in Renal Transplanted Patients. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 827-833.	1.0	7
615	Lack of an effect of <i>CYP3A4</i> and <i>MDR1</i> gene polymorphisms on colchicine pharmacogenetics in the treatment of Familial Mediterranean fever. <i>Genetics and Molecular Research</i> , 2013, 12, 3521-3528.	0.3	12

#	ARTICLE	IF	CITATIONS
616	Expression of multidrug resistance protein 1 and multidrug resistance-associated protein 1 in peripheral blood lymphocytes amongst children and young adults. Central-European Journal of Immunology, 2013, 4, 518-529.	0.4	0
617	Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant Therapy. International Journal of Genomic Medicine, 2013, 1, .	0.0	1
618	Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant. Genetics and Molecular Research, 2013, 12, 801-808.	0.3	6
619	Drug-Induced Trafficking of P-Glycoprotein in Human Brain Capillary Endothelial Cells as Demonstrated by Exposure to Mitomycin C. PLoS ONE, 2014, 9, e88154.	1.1	34
620	The Utility of Single Nucleotide DNA Variations as Predictors of Postoperative Pain. Journal of Anesthesia & Clinical Research, 2014, 05, .	0.1	2
621	Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 304.	0.5	28
622	Implication of P-Glycoprotein in Formation of Depression-Prone Personality: Association Study between the C3435TMDR1 Gene Polymorphism and Interpersonal Sensitivity. Neuropsychobiology, 2014, 69, 89-94.	0.9	8
623	Frequency and genotype distribution of ABCB1 gene polymorphisms among Maharashtrian population of Central India. Xenobiotica, 2014, 44, 579-582.	0.5	4
624	Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics, 2014, 15, 1105-1116.	0.6	75
625	Impact of <i>ABCB1</i> single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in <i>FLT3</i> wild-type <i>de novo</i> AML patients with normal karyotype. British Journal of Haematology, 2014, 167, 671-680.	1.2	13
626	Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction. Pharmacogenomics, 2014, 15, 1791-1806.	0.6	10
627	Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma. International Journal of Molecular Sciences, 2014, 15, 6703-6716.	1.8	18
628	ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncology Letters, 2014, 7, 1313-1319.	0.8	33
629	Genotype Variability and Haplotype Profile of Abcb1 (Mdr1) Gene Polymorphisms in Macedonian Population. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2014, 35, 121-133.	0.2	6
630	Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology, 2014, 19, 123-128.	0.7	29
631	Preventing HIV infection: Pre-exposure and postexposure prophylaxis. IUBMB Life, 2014, 66, 453-461.	1.5	3
632	Relationship of <i>CYP3A5</i> genotype and <i>ABCB1</i> diplotype to tacrolimus disposition in Brazilian kidney transplant patients. British Journal of Clinical Pharmacology, 2014, 78, 364-372.	1.1	34
633	P-glycoprotein in the Developing Human Brain. Therapeutic Drug Monitoring, 2014, 36, 699-705.	1.0	22

#	ARTICLE	IF	CITATIONS
634	ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition. <i>Cancer Drug Discovery and Development</i> , 2014, , 373-400.	0.2	8
635	Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 88-93.	0.9	63
636	Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia. <i>Tumor Biology</i> , 2014, 35, 10969-10975.	0.8	16
637	Genetic markers for prediction of treatment outcomes in ovarian cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 401-410.	0.9	16
638	Is There a Role for MDR1, EPHX1 and Protein Z Gene Variants in Modulation of Warfarin Dosage? A Study on a Cohort of the Egyptian Population. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 73-83.	1.6	18
640	Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1337-1354.	1.5	119
641	<i>MDR1</i> Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer. <i>Cancer Research</i> , 2014, 74, 598-608.	0.4	103
642	The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. <i>Epilepsy Research</i> , 2014, 108, 1052-1067.	0.8	17
643	Expression of breast cancer resistance protein in peripheral T cell subsets from HIV-1-infected patients with antiretroviral therapy. <i>Molecular Medicine Reports</i> , 2014, 10, 939-946.	1.1	7
645	Inter-ethnic differences in drug response: Implications for drug development and complying with drug regulation. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 88-98.	2.1	14
646	Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 309-320.	2.3	23
647	Quantitation of the impact of <i>CYP3A5</i> A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 387-394.	0.8	8
648	Effects of the ABCB1 (1199G > A) Polymorphism on Steroid Sex Hormone-Induced P-Glycoprotein Expression, ATPase Activity, and Hormone Efflux. <i>Medical Sciences (Basel, Switzerland)</i> , 2015, 3, 124-137.	1.3	4
649	MDR1 Polymorphisms and Idiopathic Nephrotic Syndrome in Slovak Children: Preliminary Results. <i>Medical Science Monitor</i> , 2015, 21, 59-68.	0.5	15
650	Association of MDR1 C3435T and C1236T single nucleotide polymorphisms with male factor infertility. <i>Genetics and Molecular Research</i> , 2015, 14, 6330-6339.	0.3	7
651	Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription. <i>Current Drug Metabolism</i> , 2015, 16, 17-45.	0.7	10
652	Effect of single nucleotide polymorphisms in the ATP-binding cassette B1 gene on the clinical outcome of traumatic brain injury. <i>Genetics and Molecular Research</i> , 2015, 14, 10948-10953.	0.3	10
653	Genotype and Haplotype Analysis of <i>ABCB1</i> at 1236, 2677 and 3435 among Jordanian Population. <i>Tropical Journal of Pharmaceutical Research</i> , 2015, 14, 1013.	0.2	1

#	ARTICLE	IF	CITATIONS
654	The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 117-125.	1.2	20
655	Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions. <i>Pharmaceutical Research</i> , 2015, 32, 2477-502.	1.7	14
656	ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: a Next Generation Sequencing approach. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1515-9.	1.4	3
657	Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2015, 16, 2019-2034.	0.6	49
658	Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. <i>Clinical Pharmacokinetics</i> , 2015, 54, 147-166.	1.6	137
659	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. <i>Advances in Cancer Research</i> , 2015, 125, 217-243.	1.9	43
660	Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. <i>Gene</i> , 2015, 558, 200-207.	1.0	48
661	Drug-Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 916-929.	1.6	21
662	Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 293-302.	0.8	21
663	Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 959-965.	0.8	21
664	Predicting survival using clinical risk scores and non-HLA immunogenetics. <i>Bone Marrow Transplantation</i> , 2015, 50, 1445-1452.	1.3	14
665	Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients. <i>Tumor Biology</i> , 2015, 36, 2863-2868.	0.8	6
666	Association of ABCB1/MDR1 polymorphisms in patients with glucocorticoid-induced osteonecrosis of the femoral head: Evidence for a meta-analysis. <i>Gene</i> , 2015, 569, 34-40.	1.0	14
667	Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. <i>Clinical Pharmacokinetics</i> , 2015, 54, 709-735.	1.6	207
668	Association of ACE and MDR1 Gene Polymorphisms with Steroid Resistance in Children with Idiopathic Nephrotic Syndrome. <i>Genetic Testing and Molecular Biomarkers</i> , 2015, 19, 454-456.	0.3	9
669	Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 855-862.	2.8	4
670	Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1109-1121.	1.1	18
672	Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome. <i>Pharmacogenomics</i> , 2015, 16, 1631-1648.	0.6	23

#	ARTICLE	IF	CITATIONS
673	<i>ABCB1</i> polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. <i>Cancer Science</i> , 2015, 106, 86-93.	1.7	59
674	Genetic polymorphism of <i>ABCB1</i> gene (C3435T) in patients with inflammatory bowel diseases. Is there any gender dependency?. <i>Pharmacological Reports</i> , 2015, 67, 294-298.	1.5	6
675	<i>ABCB11</i> and <i>ABCB1</i> gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 63-69.	2.5	13
676	The role of Multidrug Resistance-1 (<i>MDR1</i>) variants in response to atorvastatin among Jordanians. <i>Cytotechnology</i> , 2015, 67, 267-274.	0.7	7
677	Contribution of <i>MDR1</i> gene polymorphisms on <i>IBD</i> predisposition and response to glucocorticoids in <i>IBD</i> in a Chinese population. <i>Journal of Digestive Diseases</i> , 2015, 16, 22-30.	0.7	24
678	Single Nucleotide Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome. <i>International Journal of Nephrology</i> , 2016, 2016, 1-12.	0.7	12
679	The effect of <i>ABCB1</i> polymorphisms on the outcome of breast cancer treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 47.	0.4	35
680	Association of <i>ABCB1</i> and <i>SLC22A16</i> Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0168519.	1.1	25
681	Association between C3435T polymorphism of <i>MDR1</i> gene and the incidence of drug-resistant epilepsy in the population of Polish children. <i>Behavioral and Brain Functions</i> , 2016, 12, 21.	1.4	21
682	Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of <i>CYP2C9</i> , <i>CYP2C19</i> , and <i>ABCB1</i> . <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1570-1581.	1.0	17
683	Significant impacts of <i>CYP3A4*1G</i> and <i>CYP3A5*3</i> genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 341-347.	0.7	6
685	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. <i>Pharmacogenomics</i> , 2016, 17, 463-471.	0.6	8
686	Association between <i>MDR1</i> gene polymorphisms and the risk of Crohn's disease in a cohort of Algerian pediatric patients. <i>Pediatric Research</i> , 2016, 80, 837-843.	1.1	7
687	Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome. <i>Chemical Research in Toxicology</i> , 2016, 29, 1591-1601.	1.7	56
689	Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. <i>Journal of Clinical Pharmacology</i> , 2016, 56, S40-58.	1.0	9
690	Pharmacogenomics and histone deacetylase inhibitors. <i>Pharmacogenomics</i> , 2016, 17, 1807-1815.	0.6	27
691	Polymorphisms in <i>CYP1A1</i> and <i>CYP3A5</i> Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting. <i>Pharmacotherapy</i> , 2016, 36, 1238-1244.	1.2	6
692	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of <i>MDR1</i> and other membrane transporters. <i>Genome Medicine</i> , 2016, 8, 119.	3.6	10

#	ARTICLE	IF	CITATIONS
693	Everolimus pharmacokinetics and its exposureâ€“toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 63-71.	1.1	34
694	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S57-S69.	1.0	54
695	Forensic Investigation of Methadone Concentrations in Deceased Breastfed Infants. <i>Journal of Forensic Sciences</i> , 2016, 61, 576-580.	0.9	10
696	Genetic Polymorphisms of P-glycoprotein: Echoes of Silence. , 2016, , 105-134.		3
697	Impacts of <i>ABCB1</i> (G1199A) polymorphism on resistance, uptake, and efflux to steroid drugs. <i>Xenobiotica</i> , 2016, 46, 948-952.	0.5	11
698	Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2016, 35, 341-349.	1.0	30
699	Effect of the CYP3A5 and <i>ABCB1</i> genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. <i>Pharmacogenomics Journal</i> , 2016, 16, 47-53.	0.9	24
700	<i>ABCB1</i> and <i>SLCO1B3</i> Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population. <i>Pharmacology</i> , 2017, 99, 250-258.	0.9	8
701	Sex differences in transplantation. <i>Transplantation Reviews</i> , 2017, 31, 145-150.	1.2	43
702	ATPâ€“binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1562-1569.	1.4	10
704	Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2345-2356.	1.6	2
705	Fexofenadine, a Putative <i>In Vivo</i> P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 989-996.	2.3	10
706	A PRISMA-compliant meta-analysis of <i>MDR1</i> polymorphisms and idiopathic nephrotic syndrome. <i>Medicine (United States)</i> , 2017, 96, e7191.	0.4	11
707	Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 291-303.	0.8	7
708	CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 804-813.	0.9	20
709	Relationship Between <i>ABCB1</i> Polymorphisms and Cold Pain Sensitivity Among Healthy Opioid-naïve Malay Males. <i>Pain Practice</i> , 2017, 17, 930-940.	0.9	6
710	<i>ABCB1</i> gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. <i>Surgical Oncology</i> , 2017, 26, 473-482.	0.8	14
711	Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of <i>ABCB1</i> . <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 567-579.	0.8	6

#	ARTICLE	IF	CITATIONS
712	Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 329-336.	0.7	61
713	Associations between MDR1 C3435T polymorphism and drug-resistant epilepsy in the Polish population. <i>Acta Neurologica Belgica</i> , 2017, 117, 153-158.	0.5	18
714	Evaluation of the Role of ABCB1 gene Polymorphic Variants on Psychiatric Disorders Predisposition in Macedonian Population. <i>Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki</i> , 2017, 38, 71-88.	0.2	1
715	ABCB1 genetic variants in leukemias: current insights into treatment outcomes. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 169-181.	0.4	15
716	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 803-817.	2.3	99
717	Pharmacogenetics of Opioid Use Disorder Treatment. <i>CNS Drugs</i> , 2018, 32, 305-320.	2.7	24
718	P-glycoprotein polymorphism and levothyroxine bioavailability in hypothyroid patients. <i>Saudi Pharmaceutical Journal</i> , 2018, 26, 274-278.	1.2	3
719	Influence of <i><sc>CYP</sc>2D6</i>, <i><sc>CYP</sc>3A4</i>, <i><sc>CYP</sc>3A5</i> and <i><sc>ABCB</sc>1</i> Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 596-605.	1.2	55
720	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 474-485.	1.2	51
721	ABCB1 gene polymorphism in nephrotic syndrome. <i>Comparative Clinical Pathology</i> , 2018, 27, 1181-1189.	0.3	2
722	Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. <i>Pharmacogenomics</i> , 2018, 19, 475-393.	0.6	11
723	Molecular Biology of ABC Transporters. , 2018, , 180-220.		0
724	ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics. <i>Journal of Personalized Medicine</i> , 2018, 8, 40.	1.1	9
725	The dawn of precision medicine in HIV: state of the art of pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1581-1595.	0.9	14
726	Bisphenol A (BPA) and bisphenol S (BPS) alter the promoter activity of the ABCB1 gene encoding P-glycoprotein in the human placenta in a haplotype-dependent manner. <i>Toxicology and Applied Pharmacology</i> , 2018, 359, 47-54.	1.3	22
727	Genetic variability among Mexican Mestizo and Amerindian populations based on three ABCB1 polymorphisms. <i>Molecular Biology Reports</i> , 2018, 45, 2525-2533.	1.0	7
728	Differential effect of ABCB1 haplotypes on promoter activity. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 69-77.	0.7	8
729	Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 542.	1.6	16

#	ARTICLE	IF	CITATIONS
730	MDR1 gene polymorphisms are associated with ulcerative colitis in a cohort of Serbian patients with inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0194536.	1.1	21
731	Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome. <i>Journal of Perinatology</i> , 2019, 39, 1370-1376.	0.9	16
732	Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. <i>Frontiers in Pharmacology</i> , 2019, 10, 832.	1.6	12
733	Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention. <i>Clinical Therapeutics</i> , 2019, 41, 1199-1212.e2.	1.1	23
734	Translating Pharmacogenetics and Pharmacogenomics to the Clinic: Progress in Human and Veterinary Medicine. <i>Frontiers in Veterinary Science</i> , 2019, 6, 22.	0.9	12
735	Association of a genetic variant in ATP-binding cassette subfamily B member 1 gene with poor prognosis in patients with squamous cell carcinoma of the esophagus. <i>IUBMB Life</i> , 2019, 71, 1252-1258.	1.5	7
736	Dextromethorphan Analgesia in a Human Experimental Model of Hyperalgesia. <i>Anesthesiology</i> , 2019, 131, 356-368.	1.3	11
737	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	1.0	374
738	Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway. <i>FASEB Journal</i> , 2019, 33, 3420-3436.	0.2	40
739	Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 1896-1904.	1.6	28
740	The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia. <i>Pharmacological Reports</i> , 2019, 71, 90-95.	1.5	5
741	Influence of ABCB1 (1236C>T, 2677G>T and 3435C>T) polymorphisms on the transport of P-gp-mediated sunitinib in Caco-2 cell line. <i>Xenobiotica</i> , 2020, 50, 346-353.	0.5	2
742	MDR1 gene polymorphisms and acute myeloid leukemia AML susceptibility in A Moroccan adult population: A case-control study and meta-analysis. <i>Current Research in Translational Medicine</i> , 2020, 68, 29-35.	1.2	3
743	The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109657.	2.5	7
744	Genetic Polymorphisms in Multispecific Transporters Mitigate Mercury Nephrotoxicity in an Artisanal and Small-Scale Gold Mining Community in Colombia. <i>Toxicological Sciences</i> , 2020, 178, 338-346.	1.4	7
745	Effect of ABC transporter expression and mutational status on survival rates of cancer patients. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110718.	2.5	21
746	Variantes del gen ABCB1 como factores de riesgo y factores moduladores de la edad de inicio en pacientes mexicanos con enfermedad desmielinizante. <i>Neurología</i> , 2023, 38, 65-74.	0.3	2
747	Gender Differences in Drug Therapy. , 2020, , 547-570.		1

#	ARTICLE	IF	CITATIONS
748	ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Archives of Pharmacal Research, 2020, 43, 1187-1196.	2.7	19
749	Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Scientific Reports, 2020, 10, 12457.	1.6	12
750	Beyond Single Nucleotide Polymorphisms: CYP3A5 ⁻³ -6 ⁻⁷ Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients. Frontiers in Genetics, 2020, 11, 889.	1.1	6
751	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. American Journal of Drug and Alcohol Abuse, 2020, 46, 761-768.	1.1	3
752	Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine-N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients. Frontiers in Oncology, 2020, 10, 1348.	1.3	7
753	Impact of variants in ATP-binding cassette transporters on breast cancer treatment. Pharmacogenomics, 2020, 21, 1299-1310.	0.6	9
754	Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking Cessation. Frontiers in Genetics, 2020, 11, 571997.	1.1	8
755	Variant discovery using next-generation sequencing and its future role in pharmacogenetics. Pharmacogenomics, 2020, 21, 471-486.	0.6	9
756	Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy. Pharmacogenomics Journal, 2020, 20, 845-856.	0.9	6
757	<p>Single Nucleotide Variants Associated with Colorectal Cancer Among Iranian Patients: A Narrative Review</p>. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 167-180.	0.4	2
759	The role of candidate genetic polymorphisms in the interaction between voriconazole and cyclosporine in patients undergoing allogeneic hematopoietic cell transplantation: An explorative study. Current Research in Translational Medicine, 2020, 68, 51-58.	1.2	1
760	Peripheral neuropathy in hematologic malignancies – Past, present and future. Blood Reviews, 2020, 43, 100653.	2.8	16
761	Gender effect on the pharmacokinetics of thymoquinone: Preclinical investigation and in silico modeling in male and female rats. Saudi Pharmaceutical Journal, 2020, 28, 403-408.	1.2	8
762	P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a. Biochemical Pharmacology, 2021, 183, 114313.	2.0	8
763	Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. Journal of Personalized Medicine, 2021, 11, 37.	1.1	60
764	Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3-10.	0.5	9
765	A Study on the Correlation Between MDR1 Polymorphism and Clopidogrel Resistance in Hui Patients Treated with Percutaneous Coronary Intervention. International Journal of General Medicine, 2021, Volume 14, 665-671.	0.8	3
766	Influence of ABCB1 gene polymorphism on concentration-to dose ratio and adverse effects of tacrolimus in Pakistani liver transplant recipients. Pakistan Journal of Medical Sciences, 2021, 37, 689-694.	0.3	7

#	ARTICLE	IF	CITATIONS
767	ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 369-396.	1.5	37
768	Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine. Clinical Pharmacology and Therapeutics, 2021, 110, 897-908.	2.3	25
769	Association between <i>ABCB1</i> polymorphisms and response to antiepileptic drugs among Jordanian epileptic patients. Neurological Research, 2021, 43, 724-735.	0.6	6
770	C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Case-Control and Meta-Analysis Study. Genes, 2021, 12, 1419.	1.0	5
771	<i>ABCB1</i> polymorphism in clopidogrel-treated Montenegrin patients. Open Life Sciences, 2021, 16, 142-149.	0.6	1
772	The Role of Pharmacogenetics/Pharmacogenomics in Drug Development and Regulatory Review: Current Status. , 0, , 49-70.		2
773	Recent Progress in Inflammatory Bowel Disease Genetics. Advances in Experimental Medicine and Biology, 2006, 579, 24-34.	0.8	1
774	ADME Pharmacogenetics and Its Impact on Drug-Drug Interactions. , 2010, , 51-74.		3
775	Pharmacogenetics in Rheumatoid Arthritis. Methods in Molecular Biology, 2014, 1175, 625-660.	0.4	3
776	ABC Transporter Proteins and Cellular Drug Resistance. , 2004, , 129-162.		2
777	New and Revised Concepts in Multidrug Resistance. , 2006, , 261-282.		1
778	Pharmacogenetics of Membrane Transporters. Methods in Molecular Biology, 2008, 448, 41-62.	0.4	21
779	Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy. Methods in Molecular Biology, 2008, 448, 63-76.	0.4	41
780	Assay-Assisted Treatment Selection for Women with Breast or Ovarian Cancer. Recent Results in Cancer Research, 2003, 161, 126-145.	1.8	14
781	INTRODUCTION TO DRUG METABOLISM. , 2004, , 825-829.		4
782	Principles of Clinical Pharmacology. , 2012, , 165-171.		1
784	Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut, 2003, 52, 759-766.	6.1	173
785	Effect of Multidrug-Resistant 1 (MDR1) and CYP3A4*1B Polymorphisms on Cyclosporine-Based Immunosuppressive Therapy in Renal Transplant Patients. Annals of Transplantation, 2019, 24, 108-114.	0.5	11

#	ARTICLE	IF	CITATIONS
786	Does G2677T Polymorphism of the MDR1 Gene Make a Difference in the Therapeutic Response to Paroxetine in Depressed Patients in a Slovakian Population?. <i>Medical Science Monitor</i> , 2018, 24, 3136-3145.	0.5	5
787	A Comprehensive Investigation on Common Polymorphisms in the MDR1/ABCB1 Transporter Gene and Susceptibility to Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e32784.	1.1	30
788	Functional Impact of ABCB1 Variants on Interactions between P-Glycoprotein and Methadone. <i>PLoS ONE</i> , 2013, 8, e59419.	1.1	36
789	Association of Polymorphisms in Pharmacogenetic Candidate Genes (OPRD1, GAL, ABCB1, OPRM1) with Opioid Dependence in European Population: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e75359.	1.1	55
790	ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines. <i>PLoS ONE</i> , 2014, 9, e91555.	1.1	38
791	High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. <i>Brazilian Journal of Medical and Biological Research</i> , 2005, 38, 1389-1397.	0.7	46
792	Frequency of G2677T/A and C3435T polymorphisms of MDR1 gene in preeclamptic women. <i>Ginekologia Polska</i> , 2013, 84, 781-7.	0.3	6
793	Combination analysis of <i>NOS3</i> , <i>ABCB1</i> and <i>IL23R</i> polymorphisms with alcohol-induced osteonecrosis of the femoral head risk in Chinese males. <i>Oncotarget</i> , 2017, 8, 33770-33778.	0.8	10
794	The Impact of Opioid Analgesics and the Pharmacogenomics of ABCB1 in Opioid Dependence and Pharmacotherapies: A Short Review. <i>Open Pain Journal</i> , 2020, 13, 7-21.	0.4	7
795	Haplotype Analysis of MDR1 and Risk for Cervical Cancer in Northeastern Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1815-1819.	0.5	3
796	Role of Opioid Rotation and Tapering in Managing Opioid-Induced Hyperalgesia. , 2009, , 134-163.		1
797	Variations in Opioid Responsiveness. <i>Pain Physician</i> , 2008, 2;11, 237-248.	0.3	63
798	Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2006, 12, 3636.	1.4	125
799	Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 1095.	1.4	116
800	The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2013, 24, 1125.	0.4	7
801	Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. <i>Genetics and Molecular Research</i> , 2008, 7, 177-183.	0.3	33
802	Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2006, 44, 605-613.	0.3	9
803	Is the MDR1 C3435T Polymorphism Responsible for Oral Mucositis in Children with Acute Lymphoblastic Leukemia?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 5251-5255.	0.5	19

#	ARTICLE	IF	CITATIONS
804	Associations of ABCB1 and XPC Genetic Polymorphisms with Susceptibility to Colorectal Cancer and Therapeutic Prognosis in a Chinese Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 3085-3091.	0.5	19
805	MDR1 C3435T and C1236T Polymorphisms: Association with High-risk Childhood Acute Lymphoblastic Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2839-2843.	0.5	25
806	Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 250-255.	0.9	14
807	MDR1 C3435T and C1236T Polymorphisms: Association with High-risk Childhood Acute Lymphoblastic Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2839-2843.	0.5	25
808	MDR1 C3435T and C1236T Polymorphisms: Association with High-risk Childhood Acute Lymphoblastic Leukemia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2839-2843.	0.5	25
809	Intestinal Drug Transport: Stereochemical Aspects. <i>Handbook of Experimental Pharmacology</i> , 2003, , 251-288.	0.9	1
810	Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy. , 2004, , 471-477.		1
811	Scientific, Mechanistic and Regulatory Issues with Pharmacokinetic Drug-Drug Interactions. <i>Drugs and the Pharmaceutical Sciences</i> , 2004, , 297-343.	0.1	0
812	Drug Transporters. <i>Drugs and the Pharmaceutical Sciences</i> , 2004, , 111-136.	0.1	0
813	Principles of Clinical Pharmacology. , 2005, , 87-94.		2
814	Pharmacogenetics of Drug Transporters. <i>Drugs and the Pharmaceutical Sciences</i> , 2005, , 109-155.	0.1	2
815	Pharmacogenetics and Cardiac Ion Channels. <i>Drugs and the Pharmaceutical Sciences</i> , 2005, , 207-220.	0.1	0
816	Pharmacogenetics in Infectious Diseases. , 2006, , 155-187.		0
817	The Correlation between Genetic Polymorphism of OPRM1 (A118G) and MDR1 (C3435T) with Analgesia and the Adverse Effects by Epidural Morphine. <i>Daehan Macwi'gwa Haghoeji</i> , 2007, 52, 16.	0.2	2
819	Drug Transporters. , 2009, , 45-84.		3
820	Antiretroviral Therapy and Communities of Color. , 2009, , 33-51.		0
821	SEX DIFFERENCES IN PHARMACOLOGY. , 2009, , 251-256.		0
823	Gender and pharmacokinetics*. , 2012, , 226-230.		0

#	ARTICLE	IF	CITATIONS
824	ABC transporters: circadian rhythms and sex-related differences. Journal of Marmara University Institute of Health Sciences, 2013, , 1.	0.1	0
825	Pharmacogenomics and Personalized Medicine for Cancer. , 2013, , 215-235.		3
826	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. , 2013, , 469-506.		0
827	Proarrhythmia (Secondary). , 2014, , 345-350.		0
828	Drugâ€™Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective. RSC Drug Discovery Series, 2015, , 263-282.	0.2	0
829	Principles of Pharmacology. , 2016, , 1825-1842.		0
830	Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development. , 2018, , 133-175.		0
831	Gender Differences in Drug Therapy. , 2019, , 1-24.		0
832	ABCB1 Polymorphisms in High-Dose and Low-Dose Dependent Patients Under Methadone Maintenance Treatment in an Iranian Population. Iranian Journal of Psychiatry and Behavioral Sciences, 2019, 13, .	0.1	2
833	â€™Getting Involved in Gambling as a Way of Escaping from Violenceâ€™: The Meaning of Gambling based on the Experience of Domestic Violence in Problematic Gamblers. Journal of Korean Academy of Psychiatric and Mental Health Nursing, 2020, 29, 119-132.	0.0	0
834	Pharmacogenomic mechanisms of drug toxicity. , 2022, , 303-322.		1
835	Predicting Opioid Responsiveness in Pediatric Patients. , 2020, , 95-110.		0
836	Resistance to Anti-Thyroid Drugs in Gravesâ€™ Disease: Clinical-Biological Characteristics and Alternative Therapy in Tropical Area. Open Journal of Endocrine and Metabolic Diseases, 2020, 10, 147-153.	0.2	1
837	Gastroenterologic and Hepatic Diseases. , 2006, , 92-118.		0
838	State-of-the-Art Lecture I: Pharmacogenetics. , 0, , 3-7.		0
840	Profiling single nucleotide polymorphisms (SNPs) across intracellular folate metabolic pathway in healthy Indians. Indian Journal of Medical Research, 2011, 133, 274-9.	0.4	11
841	Association of ABCB1 polymorphisms and ulcerative colitis susceptibility. International Journal of Clinical and Experimental Pathology, 2015, 8, 943-7.	0.5	5
842	Two SNPs of ATP-binding cassette B1 gene on the risk and prognosis of colorectal cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 3083-9.	0.5	11

#	ARTICLE	IF	CITATIONS
843	ABCB1 polymorphism and susceptibility to acute lymphoblastic leukemia: a meta analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 7585-91.	1.3	2
844	ABCB1 polymorphisms associated with osteonecrosis of the femoral head. International Journal of Clinical and Experimental Pathology, 2015, 8, 15240-4.	0.5	4
845	Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?. American Journal of Cancer Research, 2016, 6, 1583-98.	1.4	33
846	Mechanisms and genetics of drug transport. , 2022, , 213-239.		1
847	ATP binding cassette transporters and cancer: revisiting their controversial role. Pharmacogenomics, 2021, 22, 1211-1235.	0.6	12
848	Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2022, 11, 264-272.	0.6	2
849	Peculiarities of dabigatran pharmacogenetics: literature review. Journal of Arrhythmology, 2022, 29, 39-44.	0.1	0
850	ABCB1 gene variants as risk factors and modulators of age of onset of demyelinating disease in Mexican patients. Neurología (English Edition), 2022, , .	0.2	0
851	Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives. Pharmaceutics, 2022, 14, 559.	2.0	6
856	Pharmacogenetics of Drug Disposition. , 0, , 385-421.		0
858	Influence of Single-Nucleotide Polymorphisms in the Multidrug Resistance-1 Gene on the Cellular Export of Nelfinavir and Its Clinical Implication for Highly Active Antiretroviral Therapy. Antiviral Therapy, 2004, 9, 929-935.	0.6	29
860	Trivariate Linear Regression and Machine Learning Prediction of Possible Roles of Efflux Transporters in Estimated Intestinal Permeability Values of 301 Disparate Chemicals. Biological and Pharmaceutical Bulletin, 2022, , .	0.6	2
861	Evaluation of Pharmacogenetics of Drug-Metabolizing Enzymes and Drug Efflux Transporter in Renal Transplants Receiving Immunosuppressants. Journal of Personalized Medicine, 2022, 12, 823.	1.1	5
862	Association between polymorphisms of ABCB1 and prognosis in esophageal squamous cell carcinoma patients treated with taxane. Journal of Gene Medicine, 0, , .	1.4	0
864	Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology, 2022, 90, 29-44.	1.1	2
865	Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic and Clinical Pharmacology and Toxicology, 2022, 131, 311-324.	1.2	28
866	Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis. Methods in Molecular Biology, 2022, , 527-567.	0.4	1
868	The Role of ABC Transporters in the Actions of Drugs of Abuse. , 2022, , 635-652.		0

#	ARTICLE	IF	CITATIONS
869	Distribution of the functional MDR1 C3435T polymorphism in the Han population of China. Swiss Medical Weekly, 0, , .	0.8	4
871	Joint Analysis of Phenotypic and Genomic Diversity Sheds Light on the Evolution of Xenobiotic Metabolism in Humans. Genome Biology and Evolution, 2022, 14, .	1.1	1
872	Some pharmacogenetic aspects of the <i>ABCB1</i> gene in lopinavir / ritonavir concentration variability in children with HIV infection: A pilot study. Acta Biomedica Scientifica, 2022, 7, 53-61.	0.1	0
873	Cannabis Pharmacogenomics: A Path to Personalized Medicine. Current Issues in Molecular Biology, 2023, 45, 3479-3514.	1.0	2
874	Role of <i>MDR1</i> Gene Polymorphisms in Human Male Infertility: A Meta-Analysis. American Journal of Men's Health, 2023, 17, 155798832311666.	0.7	0